Tirofiban
- Generic Name
- Tirofiban
- Brand Names
- Aggrastat
- Drug Type
- Small Molecule
- Chemical Formula
- C22H36N2O5S
- CAS Number
- 144494-65-5
- Unique Ingredient Identifier
- GGX234SI5H
- Background
Tirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
- Indication
For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.
- Associated Conditions
- Cardiovascular Events
The Effect Of Antiplatelets Therapy On Saphenous Vein Coronary Artery Bypass Graft Patency
- Conditions
- Coronary Artery Disease
- Interventions
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2012-05-15
- Lead Sponsor
- Prince Sultan Cardiac Center, Adult Cardiology Department.
- Target Recruit Count
- 200
- Registration Number
- NCT01598337
- Locations
- 🇸🇦
Prince Sultan Cardiac Center, Riyadh, Saudi Arabia
Shortened Aggrastat® Versus Integrilin in Percutaneous Coronary Intervention
- Conditions
- Myocardial InfarctionAcute Coronary SyndromesUnstable Angina
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2021-05-13
- Lead Sponsor
- Medicure
- Target Recruit Count
- 535
- Registration Number
- NCT01522417
- Locations
- 🇺🇸
Doylestown Hospital, Doylestown, Pennsylvania, United States
🇺🇸Redmond Regional Medical Center, Rome, Georgia, United States
🇺🇸Osceola Regional Medical Center, Kissimmee, Florida, United States
Tirofiban in Stenting for Long Coronary Lesion
- Conditions
- Coronary Artery Disease
- Interventions
- Drug: normal saline solution
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2015-07-14
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 748
- Registration Number
- NCT01498003
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse
- Conditions
- ST Segment Elevation Myocardial Infarction
- Interventions
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- Università degli Studi di Ferrara
- Target Recruit Count
- 100
- Registration Number
- NCT01336348
- Locations
- 🇮🇹
Cardiology Unit, Ferrara, Italy
Aggrastat Truncated Length Against Standard Therapies in Percutaneous Coronary Intervention
- Conditions
- Myocardial InfarctionUnstable AnginaPercutaneous Coronary InterventionAcute Coronary Syndromes
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-11-22
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- Medicure
- Registration Number
- NCT01245725
Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients
- Conditions
- Acute Myocardial Infarction
- Interventions
- First Posted Date
- 2010-04-22
- Last Posted Date
- 2010-04-22
- Lead Sponsor
- Kosuyolu Heart Hospital
- Target Recruit Count
- 49
- Registration Number
- NCT01109134
Tirofiban and Enoxaparin in High Risk Coronary Intervention
- Conditions
- Acute Coronary Syndrome
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2010-03-24
- Lead Sponsor
- The Prince Charles Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00790387
- Locations
- 🇦🇺
The Prince Charles Hospital, Brisbane, Queensland, Australia
Shanghai Registry of Acute Coronary Events
- Conditions
- Coronary Artery DiseaseAcute Coronary Syndrome
- Interventions
- Device: drug-eluting stent
- First Posted Date
- 2008-07-11
- Last Posted Date
- 2016-10-13
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 20000
- Registration Number
- NCT00713557
- Locations
- 🇨🇳
Dept. of Cardiology, Ruijin Hospital, Shanghai, Shanghai, China
The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2008-02-08
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 40
- Registration Number
- NCT00611169
Safety of High-dose Tirofiban During Coronary Angioplasty
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2011-02-02
- Lead Sponsor
- S. Anna Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT00566891
- Locations
- 🇮🇹
S Anna Hospital, Catanzaro, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.